MDACC Study No:2010-0029 ( NCT No: NCT00884312)
Title:An Open-Label, Single-Arm, Phase 2 Study of Extended Carfilzomib Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols
Principal Investigator:Michael Wang
Treatment Agent:Carfilzomib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if carfilzomib continues
to be safe and effective when given long-term (beyond your previous carfilzomib
treatment) to treat myeloma.
Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase II
Treatment Agents:Carfilzomib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Onyx Therapeutics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults